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Latar belakang : Gangguan psikotik menjadi masalah kesehatan yang sangat menurunkan kualitas hidup 
penderitanya, pengobatan psikotik menggunakan obat antipsikotik ternyata menimbulkan masalah lain 
karena munculnya efek samping ekstrapiramidal (EPS), triheksifenidil merupakan pilihan terapi pendamping 
untuk menahan muculnya EPS.
Tujuan : Mengetahui gambaran penggunaan Triheksifenidil pada pasien yangmendapatkan Terapi Antipsikotik 
di RS Grhasia.
Metode : Penelitian ini merupakan penelitian non eksperimental jenis deskriptif dengan menggunakan 
pendekatan cross sectional dengan melihat data sekunder yang diperoleh dari catatan rekam medis pasien 
psikotik di RS Grhasia Yogyakarta periode Januari 2014 – Januari 2015 untuk mengetahui gambaran penggunaan 
Triheksifenidil pada pasien yang mendapatkan Terapi Antipsikotik di RS Grhasia. Penentuan sampel ditentukan 
dengan rumus slovin, olah data dilakukan dengan teknik analisis univariat.
Background:   Psychotic disorder becomes a mental health problem recently that reduce quality of life of the patient. As the matter of fact, psychotic treatment induce another problem such as extrapyramidal symtomps (EPS). 
Trihexyphenidyl is the first choice as conjuctive treatment to prevent EPS.
Objective:  To determine the description and characteristics of trihexyphenidyl utilization on patient with psychotic who receive antipsychotic therapy at Ghrasia Hospital Yogyakarta.
Methods:  This study is a non-experimental descriptive with cross sectional design with the secondary data obtained from the medical record of patients 
with psychotics on January 2014 – January 2015 to perceive the utilization of trihexyphenidyl on patient who receive antipsychotic therapy at Ghrasia hospital. The sample is determined by Slovin formula, the data is analyzed with univariat analysis technic.
Results:   The majority of psychotic patients at the Ghrasia Hospital are about 
25-40 years old (61,7%). It describes that the pattern of the psychotic disorder 
most likely happening at middle age, which 98 patients are male (63,6%). The combination of two antipsychotics becomes the most used regiment at 
Grhasia, 113 patients (73,4%) receive the combination of two antipsychotics 
theraphy, 39 patients (25,3%) receive single antipsychotic therapy and 2 
patients (1,3%) receive the combination of three antipsychotics. 136 patients 
(88,3%) receive trihexyphenidyl twice a day on undefined skizophrenia 65 
patients (42,2%) and 18 patients (11,7%) once a day. 149 patiens (96,8) are not examined before THP is given before the initiaton of the theraphy.
Conclusion:  Administration trihexiphenidyl as adjunctive therapy is given to the psychotic patients twice a day and most of them are not initiated by the examination of syndrome extrapyramidal.
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Hasil : Kategori terbanyak dari pasien psikotik di RS 
Grhasia berkisar usia25-40 tahun (61,7%). Hal ini 
memberikan gambaran bahwa pola gangguan psikotik 
cenderung terjadi pada golongan umur paruh baya, 
sebanyak 98 pasien (63,6%) berjenis kelamin laki-
laki. Regimen kombinasi dua antipsikotik menjadi 
pilihan terapi yang paling banyak digunakan di RS 
Grhasia, sebanyak 113 pasien (73,4%) mendapatkan 
terapi kombinasi dua anti psikotik, 39 pasien (25,3%) 
mendapatkan terapi antipsikotik tunggal dan 2 pasien 
(1,3%) mendapatkan terapi kombinasi tiga obat 
antipsikotik. Sebanyak 136 pasien (88,3%) pasien 
mendapatkan triheksifenidil dengan frekuensi dua 
kali sehari dengan diagnosis terbanyak skizofrenia tak 
terinci yaitu 65 pasien (42,2%) dan 18 pasien (11,7%) 
yang mendapatkan triheksifenifil dengan frekuensi 
satu kali sehari. Sebanyak 149 pasien (96,8%) tidak 
diperiksa gejala EPS sebelum pemberian triheksifenidil.
Kesimpulan : Pemberian triheksifenidil sebagai terapi 
ajungtif diberikan pada semua pasien, sebagian besar 
diberikan 2 kali sehari, dan sebagian besar tidak 
didahului dengan pemeriksaan EPS.
INTRODUCTION
According to UU no. 23 tahun 1992, health is 
defined as a well-being condition of body, mind, and social life which enables every individual to live productively in terms of socially and economically. Hence it can be concluded that 
mental health plays a major part which cannot be separated from an individual’s health.1Schizophrenia is a mental disease that has gained worldwide concern because it degrades an individual’s function as a human being. It interferes with our daily life functions, for instance 
: grooming, working or educational activities, and 
fulfilling our role to build a relationship with our surroundings.2 An epidemiology research indicates that schizophrenia occurs in every 
population with the prevalence rate 1,4 – 4,6 per 
1000 and average incidence rate at 0,16 - 0,42 per 1000 population.3Schizophrenia patients experience a disturbance to coordinate their minds, emotions, and behaviors. Every patients has different 
and wide varieties of symptoms, like : loss of communication skill, degradation of cognitive functions, loss of verbal skills, memory loss, emotional instabilities, and loss of social adaptation skills.3Antipsychotic medicine has been the 
main treatment for schizophrenia since the 
1950s. It can be used to treat the symptoms of schizophrenia, as well as a prophylaxis 
of recurrent episodes.3 The treatment for 
schizophrenia is divided into 3 stages : initial 
treatment within the first 7 days, stabilization 
treatment for 6 – 8 weeks, and maintanance therapy for 12 months after improvement of 
the first episodes. Meanwhile, for patients with recurrent episodes, maintanance therapy has to 
be done for at least 5 years. 4
About 50% of schizophrenia patients does 
not respond adequately to first-generation antipsychotic medicine.2,5 It induces unwanted 
side effects, such as : acute distonia, sub-acute Parkinson, and acathisia. Antipsychotic medicine can also induce extrapiramidal symptoms due 
to the blockage of Dopamin D2 receptors by stopping dopamine activities.6 The most common forms of extrapiramidal symptoms is the Parkinson syndrome or, so-called, Parkinsonism.7 Parkinson syndrome has similar manifestations as Parkinson disease, including bradykinesia, extremities rigidity, and unstable posture.7 These 
symptoms usually occur within the first month of treatment.8,9Extrapiramidal symptoms might occur from the very beginning of antypsychotic treatment 
―depending on the dosage of antipsychotic drugs in use. To resolve it, physicians can use anti-cholinergic medicine, such as atropine sulfate, trihexyphenidyl, and diphenhidramine. Trihexyphenidyl is the most commonly used anti-cholinergic drugs for extrapiramidal symptoms.10There are two divided opinions about the use of trihexyphenidyl to treat extrapyramidal 
symptoms ―one encourage its routine usage as prophylactic medicine, while the other is against it.11 Trihexyphenidyl has a lot of impact in antipsychotic treatment, hence a rigid guideline about its usage in antipsychotic treatment is needed.A lot of literatures has mentioned a few factors to consider before using trihexyphenidyl, including patient’s age, gender, types of antipsychotic drugs, and history of previous extrapiramidal symptoms.12 This research will describe the characteristics of trihexyphenidyl usage in patients who receive antipsychotic 
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therapy at Grhasia Hospital Yogyakarta. 
METHODSThis research is a non-analytic descriptive study with a cross sectional design, which describe the real condition to perceive the characteristics of patients who receive trihexyphenidyl treatment in companion with antipsychotic therapy at Grhasia Hospital Yogyakarta. This research was done within 
September – October 2015.
Research populations and samplesThe target population for this research is all psychotic inpatients who receive trihexyphenidyl 
within January 2014 – January 2015 at Grhasia Hospital Yogyakarta.Samples include all inpatients who receive trihexyphenidyl in companion with antipsychotic treatment, who meet the inclusion criteria, and has a complete medical record at Grhasia Hospital. 
Sample size is 154 patients― determined using the Slovin formula.The inclusion criteria in this research includes patients who is diagnosed with Schizophrenia 
(F20-F25), enlisted as inpatients at Grhasia hospital, and has a complete medical record (patient’s biodata, antipsychotic treatment history, extrapiramidal symptoms status, and history of trihexyphenidyl usage).This research excludes patients who is diagnosed with Schizophrenia accompanied with other psychiatric diagnosis, or those with incomplete medical record, or those who continues treatment at another health facilities.
Data collection was done by collecting secondary data gained from inpatients medical record which stated the usage of trihexyphenidyl in addition to antipsychotic treatment at Grhasia 
Hospital within January 2014 – January 2015.
Data Processing
Data was processed with quantitative approach. It was done through several steps, 
which were (1) Data was given a code (coding), which was done to classify data and gave a certain code to a certain data to simplify data 
input.  (2)Data management (Editing), which 
was done to filter error or unprecise data, so 
that it could be traced back and fixed.  (3) Data structuring, which was done to arrange data based on the software and analysis that would 
be used.   (4) Data entry, which was done by 
inputing computerize data to microsoft excel.  (5) 
Data cleaning, which was done to maintain the quality of data by cleaning it from possible errors. 
Data cleaning was done by tracing missing datas. 
Data Analysis
Data analysis was done with univariat analysis to determine the distribution and characteristic of trihexyphenidyl usage in inpatients who received antipsychotic therapy at Grhasia 
Hospital within January 2014 – January 2015. All variables in this research are categoric variables, hence result will be shown in proportion.
RESULTSThis research was done at Grhasia hospital 
Yogyakarta. Sample size was 154 psychotic 
inpatients within the periode of January 2014 – 
January 2015.  Result shows that most psychotic 
patients are within the age group of 25 – 40 years 
old (61,7%), mostly male (63,6%),  and mostly 
given two types antypsychotic regiments(73,4%).
In table 2, it can be seen that 96,8% of all patients were given trihexyphenidyl therapy without receiving initial EPS examinations
In table 3, it can be seen that most psychotic patients was diagnosed with Undifferentiated 
Schizophrenia, 69 patients (44,8%). While only 
2 patients (1,3%) were diagnosed with Acute 
and transient psychotic disorder unspecified.
Other diagnosis include Paranoid 
Schizophrenia in 41 patients (26,6%), 
Schizoaffective Disorder manic type in 19 
patients (12,3%), Residual Schizophrenia in 
14 patients (9,1%), and Catatonic Schizophrenia 
in 9 patients (5,8%). 
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Table 1 Demographic Characteristic of Psychotic Patients
Subject characteristics Total (N=154) %
Age (years)
18 – 25 24 15,56%
25 – 40 95 61,7%
>40 35 22,7%
Gender Female 56 36,4%Male 98 63,6%
Antipsychotic regiments
One type of antipsychotic 39 25,3%Two types of antipsychotic 113 73,4%Three types of antipsychotic 2   1,3%Table 2 Extrapiramidal examination before the initiation of Trihexyphenidyl  treatment
EPS Examination Total(N=154) %Yes 5  3,2%No 149 96,8%
Table 3  Diagnostic Distribution
 ICD-X Diagnosis Total (N=154) %
F20.3 Undifferentiated Schizophrenia 69 44,8%F20.0 Paranoid Schizophrenia 41 26,6%
F25.0 Schizoaffective Disorder, Manic type 19 12,3%
F20.5 Residual Schizophrenia 14 9,1%F20.2 Catatonic Schizophrenia 9 5,8%
F23.9 Acute and Transient Psychotic Disorder, unspecified 2 1,3%
Table 4  Trihexyphenidyl Usage Distribution
Diagnosis
THP (2 mg)
Total (%)
Once daily (%) Twice daily(%)
Undifferentiated Schizophrenia (F20.3) 4 (2,6) 65 (42,2) 69 (44,8)Paranoid Schizophrenia (F20.0) 5 (3,2) 36 (23,4) 41 (26,6)
Schizoaffective Disorder, Manic type (F 25.0) 3 (1,9) 16 (10,4) 19 (12,3)
Residual Schizophrenia (F 20.5) 4 (2,6) 10 (6,5) 14 (9,1)Catatonic Schizophrenia (F 20.2) 1 (0,6) 8 (5,2) 9 (5,8)
Acute and Transient Psychotic Disorder, 
unspecified (F 23.9) 2 (1,3) 0 (0) 2 (1,3)Total 18 (11,7) 136 (88,3) 154 (100)
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From table 4, we can conclude that in Grhasia Hospital, trihexyphenidyl was mostly 
given twice daily 136 patients (88,3%) : in 
Undifferentiated Schizophrenia 65 patients 
(42,21%), Paranoid Schizophrenia 36 patients 
(23,38%), Schizoaffective disorder manic type 
16 patients (10,39%), Residual Schizophrenia 
10 patients (6,49%), Catatonic Schizophrenia 
8 patients (5,19%), and Acute and Transient 
Psychotic Disorder unspecified 2 patients 
(1,30%). All psychotic patients was given trihexyphenidyl in 2 mg preparation.
Picture 1 Antipsychotic regiments usage in diagramTwo antipsychotic combination were the most used  treatment regiments, and chlorpromazine combined with haloperidol 
was the most prescribed combination 61patients 
(39,6%).It was mostly used in patients diagnosed 
with undifferentiated schizophrenia 31 patients 
(50,8%). In single regiments Chlozapine was 
used the most, which was in 19 from 154 patients 
(12,3%).Three drugs combination was rarely used and only contain one regiment of combination 
which include Riperidone, Chlorpromazine, and Stelazine. This was given to 2 patients who was diagnosed with Undifferentiated schizophrenia.
DISCUSSION
Most psychotic patients in RS Grhasia 
Yogyakarta is within the age group of 25-40 years old. This might indicate that the middle-aged group is more prone to psychotic disorder. Another research that was done in Padang also 
indicate the same result, where 25 patients 
(16,23%) were within the age group of 15-25 
years old, 41 patients (26,62%) were within 
the age group of 26-35 years old, 29 patients 
(18,83%) were within the age group of 36-45 
years old, 9 patients ( 5,84%) were within the 
age group of 46-55, and 4 patients (2,59%) were 
above 56 years old13. Another research in RSCM showed that most psychotic patients were within 
the age group of 31-40 years old (35%) and 
21-30 (32%) .11In this research, result showed that most 
psychotic patients are male. From 154 research 
subjects, 98 patients (63,6%)  were male, and 
only 56 patients (36,4%) were female. This result is inline with previous research in 
Bapujji Hospital where 71 psychotic patients 
(71%) were male and only 39 patients (39%) were female. According to this result, we can 
conclude that there are no significant proportion 
difference between gender (Sushma, 2015). 
Another research in RSCM Jakarta in which 97 
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psychotic patients were involved, showed 57,7% of psychotic patients were male, and the rest were female.11
In present findings, two antipsychotic drugs combination are found to be the most prescribed 
regiment. It was used in 113 patients (73,4%). 
While 39 patients (25,3%)  received single 
antipsychotic regiments, and 2 patients (1,3%) received three antipsychotic drugs combination. Previous research also showed that combination 
therapy (94%) was more preferred than 
monotherapy (6%).14Trihexyphenidyl usage as a prophylactic treatment, which means it was given before EPS occur, is expected to increase patient adherence towards treatment.11 Nevertheless, its usage is still controversial, because not only it repress the occurence of EPS and other negative side effects, but it also increase the occurence of active psychotic symptoms and altered cognitive functions in elderly patients.The high usage of trihexyphenidyl as a prophylaxis in this research might be due to a substantial amount of atypical antipsychotic drugs use and combination therapy regiments which became the predictor of EPS occurence. 15
CONCLUSION
Most psychotic patients in RS Grhasia 
Yogyakarta is within the age group of 25-40 years old. This might indicate that the middle-aged group is more prone to psychotic disorder.
Most research subjects are male. From 154 
research subjects, 98 patients (63,6%)  were 
male, and only 56 patients (36,4%) were female.Two antipsychotic drugs combination are found to be the most prescribed regiment. It 
was used in 113 patients (73,4%), while 39 
patients (25,3%)  received single antipsychotic 
regiments, and 2 patients (1,3%) received three antipsychotic drugs combination.Most patient in this research was given 
trihexyphenidyl 2 mg twice daily― 136 patients 
(88,3%), in which most of them were diagnosed 
with Undifferentiated Schizophrenia (65 pasien 
or 42,2%), while the other 18 patients (11,7%) received trihexyphenidyl 2 mg once daily.
149 patients (96,8%) was not evaluated with initial EPS examination before receiving 
trihexyphenidyl treatment, while 5 others (3,2%) undergo initial EPS examination.
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